Skip to main content

Dentine Sensitivity

0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
Calcium sodium phosphosilicateN/A
GSK
GSKLONDON, United Kingdom
1 program
Calcium sodium phosphosilicateN/A1 trial
Active Trials
NCT02371616Completed304Est. Dec 2014
Lacer
LacerSpain - Barcelona
1 program
Desensitizing tooth gelN/A1 trial
Active Trials
NCT07596797Completed31Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LacerDesensitizing tooth gel
GSKCalcium sodium phosphosilicate

Clinical Trials (2)

Total enrollment: 335 patients across 2 trials

NCT07596797LacerDesensitizing tooth gel

Evaluation of the Effect of the Gel on Sensitive Teeth

Start: Jul 2024Est. completion: Jul 202431 patients
N/ACompleted
NCT02371616GSKCalcium sodium phosphosilicate

Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity

Start: Sep 2014Est. completion: Dec 2014304 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Dentine Sensitivity | Pipeline & Competitive Landscape | Formulate